Back to results
US 2017/0000760 A1Published application
Methods for inhibiting cancer cells
AssigneesChang Gung Memorial Hospital, Chiayi, Chang Gung University
InventorsChing-Yuan WU, Kuan-Der LEE, Hong-Yo KANG, Yu-Shih LIN
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating cancer, by administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing cancer cell metastasis, by administering a therapeutically effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt thereof.
Claims13
A method for inhibiting cancer cells, comprising:
- administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I),
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 to R8 are each independently H, a deuterium, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a halogen, a substituted or unsubstituted C1-C10 alkyl group, a substituted or unsubstituted C2-C10 alkenyl group, a substituted or unsubstituted C2-C10 alkynyl group, a substituted or unsubstituted C1-C10 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C20 aryl group, a substituted or unsubstituted C6-C20 aryloxy group, a substituted or unsubstituted C6-C20 arylthio group, a substituted or unsubstituted C2-C20 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein the substituent may be at least one selected from the group consisting of a deuterium, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a halogen, a substituted or unsubstituted C1-C10 alkyl group, a substituted or unsubstituted C2-C10 alkenyl group, a substituted or unsubstituted C2-C10 alkynyl group, a substituted or unsubstituted C1-C10 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C20 aryl group, a substituted or unsubstituted C6-C20 aryloxy group, a substituted or unsubstituted C6-C20 arylthio group, a substituted or unsubstituted C2-C20 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.
1 more element
A method for reducing cancer metastasis, comprising:
- administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I),
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 to R8 are each independently H, a deuterium, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a halogen, a substituted or unsubstituted C1-C10 alkyl group, a substituted or unsubstituted C2-C10 alkenyl group, a substituted or unsubstituted C2-C10 alkynyl group, a substituted or unsubstituted C1-C10 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C20 aryl group, a substituted or unsubstituted C6-C20 aryloxy group, a substituted or unsubstituted C6-C20 arylthio group, a substituted or unsubstituted C2-C20 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein the substituent may be at least one selected from the group consisting of a deuterium, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a halogen, a substituted or unsubstituted C1-C10 alkyl group, a substituted or unsubstituted C2-C10 alkenyl group, a substituted or unsubstituted C2-C10 alkynyl group, a substituted or unsubstituted C1-C10 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C20 aryl group, a substituted or unsubstituted C6-C20 aryloxy group, a substituted or unsubstituted C6-C20 arylthio group, a substituted or unsubstituted C2-C20 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.
1 more element
Dependencies are inferred from the claim text.